Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia
Data presented at the European Hematology Association 2021 Virtual Congress show favorable safety profile and compelling clinical activity
93% overall response rate and 67% complete response rate in patients treated with modified cell manufacturing process
…
